Switch theme
Sign up to access all valuation multiples
China Traditional Chinese Medicine Holdings Co Ltd is engaged in the Chinese healthcare sector. The company functions through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. It generates maximum revenue from the Yifang segment which mainly engages in the manufacture and sales of concentrated TCM granules (CTCMG), TCM healthcare products, and TCM decoction pieces under the Yi Fang brand. The majority of the revenue of the Yi Fang segment is derived from the sales of CTCMG. Geographically, it derives a majority of its revenue from Mainland China, and also has its presence in Hong Kong and Other countries.
1992
16.8K+
LTM Revenue $2.5B
LTM EBITDA $266M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
China TCM has a last 12-month revenue (LTM) of $2.5B and a last 12-month EBITDA of $266M.
In the most recent fiscal year, China TCM achieved revenue of $2.1B and an EBITDA of $195M.
China TCM expects next 12-month revenue of XXX and NTM EBITDA of XXX
See China TCM valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.5B | XXX | $2.1B | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $1.0B | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 48% | XXX | XXX | XXX |
| EBITDA | $266M | XXX | $195M | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 9% | XXX | XXX | XXX |
| EBIT | $113M | XXX | $118M | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $62.7M | XXX | $6.9M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 0% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $6.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, China TCM's stock price is HKD 2 (or $0).
China TCM has current market cap of HKD 11.1B (or $1.4B), and EV of HKD 9.7B (or $1.2B).
See China TCM trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.4B | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, China TCM has market cap of $1.4B and EV of $1.2B.
China TCM's trades at 0.6x EV/Revenue multiple, and 6.3x EV/EBITDA.
Equity research analysts estimate China TCM's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
China TCM has a P/E ratio of 24.8x.
See valuation multiples for China TCM and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 0.5x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | 5.1x | XXX | 6.3x | XXX | XXX | XXX |
| EV/EBIT | 12.0x | XXX | 10.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 24.8x | XXX | 205.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 4.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialChina TCM's last 12 month revenue growth is 2%
China TCM's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
China TCM's rule of 40 is 16% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
China TCM's rule of X is 15% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for China TCM and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | -6% | XXX | XXX | XXX |
| Rule of 40 | 16% | XXX | 11% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 15% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
China TCM acquired XXX companies to date.
Last acquisition by China TCM was XXXXXXXX, XXXXX XXXXX XXXXXX . China TCM acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was China TCM founded? | China TCM was founded in 1992. |
| Where is China TCM headquartered? | China TCM is headquartered in Hong Kong. |
| How many employees does China TCM have? | As of today, China TCM has 16.8K+ employees. |
| Is China TCM publicy listed? | Yes, China TCM is a public company listed on HKG. |
| What is the stock symbol of China TCM? | China TCM trades under 00570 ticker. |
| When did China TCM go public? | China TCM went public in 1993. |
| Who are competitors of China TCM? | Similar companies to China TCM include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of China TCM? | China TCM's current market cap is $1.4B |
| What is the current revenue of China TCM? | China TCM's last 12 months revenue is $2.5B. |
| What is the current revenue growth of China TCM? | China TCM revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of China TCM? | Current revenue multiple of China TCM is 0.5x. |
| Is China TCM profitable? | Yes, China TCM is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of China TCM? | China TCM's last 12 months EBITDA is $266M. |
| What is China TCM's EBITDA margin? | China TCM's last 12 months EBITDA margin is 11%. |
| What is the current EV/EBITDA multiple of China TCM? | Current EBITDA multiple of China TCM is 5.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
